$0.18
(2.18%)
Add to watchlist
Create an alert
Stocks and Shares ISAElicio Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a pipeline of immunotherapies for the treatment of cancer. The Company provides a platform, amphiphile (AMP) that delivers immunotherapeutics directly to the lymph nodes (brain center) of the immune system. The Company’s clinical and preclinical pipeline includes the lymph node targeted therapeutic cancer vaccines ELI-002, which is being evaluated in a Phase II study, designed to stimulate an immune response against mutant kirsten rat sarcoma (KRAS). Its ELI-007 is being evaluated in a preclinical study for the treatment of mutant v-raf murine sarcoma viral oncogene homolog B1 (BRAF) driven cancers, and ELI-008, is being evaluated in a preclinical study for use in the treatment of mutated tumor protein p53 (TP53) expressing cancers.
Company Information
About this company
Key people
Robert Connelly
President, Chief Executive Officer, Director
Preetam Shah
Principal Financial Officer, Principal Accounting Officer, Chief Strategy Officer
Christopher M. Haqq
Executive Vice President, Head - Research and Development, Chief Medical Officer
Peter Demuth
Chief Scientific Officer
Julian Adams
Independent Chairman of the Board
Jay R. Venkatesan
Director
Carol Ashe
Independent Director
Yekaterina Chudnovsky
Independent Director
Allen R. Nissenson
Independent Director
Click to see more
Key facts
- Shares in issue17.50m
- EPICELTX
- ISINUS28657F1030
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$145.16m
- Employees32
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.